Marijen Aga, NP
Psychiatric/Mental Health · Shawnee, KSNPI 1245575547
Payments from drug & device makers
Across 718 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$2K
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$972
- plus $5K from 16 others
What the payments were for
- Food & beverage$13,058100%
- Education$630%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 106 | $1,651 |
| AbbVie | 102 | $1,567 |
| Otsuka America Pharmaceutical, Inc. | 58 | $1,449 |
| Alkermes, Inc. | 92 | $1,388 |
| Teva Pharmaceuticals USA, Inc. | 86 | $1,195 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 59 | $972 |
| Johnson & Johnson | 52 | $948 |
| E.r. Squibb & Sons, L.L.C. | 12 | $714 |
| Tris Pharma Inc | 9 | $568 |
| Lundbeck LLC | 37 | $445 |
| Neurocrine Biosciences, Inc. | 15 | $401 |
| Axsome Therapeutics, Inc. | 15 | $361 |
| Indivior Inc. | 15 | $352 |
| Vanda Pharmaceuticals Inc. | 23 | $310 |
| Corium, LLC | 14 | $279 |
| Supernus Pharmaceuticals, Inc. | 11 | $233 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $90 |
| Noven Therapeutics, LLC | 5 | $73 |
| Boehringer Ingelheim | 1 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $39 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Biogen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COBENFY$479
- Dyanavel XR$368
- Quillichew ER$368
- Quillivant$368
- REXULTI$330
- ABILIFY MAINTENA$234
- INGREZZA$138
- INVEGA TRINZA$126
- ABILIFY ASIMTUFII$124
- VRAYLAR$124
- CAPLYTA$122
- Azstarys$120
- AUSTEDO$118
- Austedo XR$106
How this compares
$13,121 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 63 | $213,697 |
| AristadaAripiprazole Lauroxil | 43 | $101,028 |
| CaplytaLumateperone Tosylate | 57 | $91,352 |
| LybalviOlanzapine/Samidorphan Malate | 49 | $75,801 |
| AustedoDeutetrabenazine | 13 | $62,434 |
| Austedo XrDeutetrabenazine | 13 | $61,713 |
| RexultiBrexpiprazole | 40 | $56,994 |
| PerserisRisperidone | 14 | $41,798 |
| Abilify MaintenaAripiprazole | 12 | $36,821 |
| Risperdal ConstaRisperidone Microspheres | 26 | $33,302 |
| Lurasidone Hcl | 113 | $24,324 |
| VraylarCariprazine Hcl | 16 | $18,844 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $17,078 |
| Clozapine | 112 | $9,994 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $7,111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Concerta | $948 | $252,692101 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,388 | $176,82992 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,195 | $124,14726 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,449 | $93,81552 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $972 | $91,35257 claims |
| Indivior Inc.Perseris | $352 | $41,79814 claims |
| AbbVieVraylar | $1,567 | $18,84416 claims |
| Axsome Therapeutics, Inc.Auvelity | $361 | $17,07816 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $39 | $7,11119 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Shawnee
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
- Theresa MuellerOverland Park$14K
- Shiney ZchariaOlathe$14K
- Deborah MurphyWichita$13K
- Anucia JosephMission$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.